ERBB2 and breast carcinoma: Asnani et al., 2020 [292], in a prospective study, revealed that HER2-positive breast cancer patients, who experienced CTRCD presented with statistically significantly altered levels of metabolites related to citric acid cycle, purine, and pyrimidine metabolites compared to patients without cardiotoxicity.